These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
546 related articles for article (PubMed ID: 22306376)
1. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Watson DS; Endsley AN; Huang L Vaccine; 2012 Mar; 30(13):2256-72. PubMed ID: 22306376 [TBL] [Abstract][Full Text] [Related]
2. Liposomal vaccine delivery systems. Henriksen-Lacey M; Korsholm KS; Andersen P; Perrie Y; Christensen D Expert Opin Drug Deliv; 2011 Apr; 8(4):505-19. PubMed ID: 21413904 [TBL] [Abstract][Full Text] [Related]
3. Designing liposomal adjuvants for the next generation of vaccines. Perrie Y; Crofts F; Devitt A; Griffiths HR; Kastner E; Nadella V Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):85-96. PubMed ID: 26576719 [TBL] [Abstract][Full Text] [Related]
4. Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines. De Serrano LO; Burkhart DJ J Nanobiotechnology; 2017 Nov; 15(1):83. PubMed ID: 29149896 [TBL] [Abstract][Full Text] [Related]
5. Liposomal subunit vaccines: effects of lipid A and aluminum hydroxide on immunogenicity. Richards RL; Alving CR; Wassef NM J Pharm Sci; 1996 Dec; 85(12):1286-9. PubMed ID: 8961140 [TBL] [Abstract][Full Text] [Related]
6. Elucidating the mechanisms of protein antigen adsorption to the CAF/NAF liposomal vaccine adjuvant systems: effect of charge, fluidity and antigen-to-lipid ratio. Hamborg M; Rose F; Jorgensen L; Bjorklund K; Pedersen HB; Christensen D; Foged C Biochim Biophys Acta; 2014 Aug; 1838(8):2001-10. PubMed ID: 24769435 [TBL] [Abstract][Full Text] [Related]
7. Liposomal presentation of antigens for human vaccines. Glück R Pharm Biotechnol; 1995; 6():325-45. PubMed ID: 7551224 [TBL] [Abstract][Full Text] [Related]
8. Predicting the influence of liposomal lipid composition on liposome size, zeta potential and liposome-induced dendritic cell maturation using a design of experiments approach. Soema PC; Willems GJ; Jiskoot W; Amorij JP; Kersten GF Eur J Pharm Biopharm; 2015 Aug; 94():427-35. PubMed ID: 26144666 [TBL] [Abstract][Full Text] [Related]
9. Liposomes as vaccine delivery systems: a review of the recent advances. Schwendener RA Ther Adv Vaccines; 2014 Nov; 2(6):159-82. PubMed ID: 25364509 [TBL] [Abstract][Full Text] [Related]
10. Sulfated archaeal glycolipid archaeosomes as a safe and effective vaccine adjuvant for induction of cell-mediated immunity. McCluskie MJ; Deschatelets L; Krishnan L Hum Vaccin Immunother; 2017 Dec; 13(12):2772-2779. PubMed ID: 28537465 [TBL] [Abstract][Full Text] [Related]
11. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624 [TBL] [Abstract][Full Text] [Related]
12. Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants. Hussain MJ; Wilkinson A; Bramwell VW; Christensen D; Perrie Y J Pharm Pharmacol; 2014 Mar; 66(3):358-66. PubMed ID: 24251796 [TBL] [Abstract][Full Text] [Related]
13. Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response. Henriksen-Lacey M; Christensen D; Bramwell VW; Lindenstrøm T; Agger EM; Andersen P; Perrie Y J Control Release; 2010 Jul; 145(2):102-8. PubMed ID: 20381556 [TBL] [Abstract][Full Text] [Related]
14. Liposomes as Adjuvants and Vaccine Delivery Systems. Tretiakova DS; Vodovozova EL Biochem (Mosc) Suppl Ser A Membr Cell Biol; 2022; 16(1):1-20. PubMed ID: 35194485 [TBL] [Abstract][Full Text] [Related]
15. Liposomes as antigen vehicles to increase immunogenicity: effects of variation of structural characteristics. Tan LS Ann Acad Med Singap; 1991 Jan; 20(1):78-83. PubMed ID: 2029169 [TBL] [Abstract][Full Text] [Related]
16. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration. Schmidt ST; Olsen CL; Franzyk H; Wørzner K; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D Eur J Pharm Biopharm; 2019 Jul; 140():29-39. PubMed ID: 31055066 [TBL] [Abstract][Full Text] [Related]
17. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice. Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014 [TBL] [Abstract][Full Text] [Related]
18. Liposome-mediated DNA vaccination: the effect of vesicle composition. Perrie Y; Frederik PM; Gregoriadis G Vaccine; 2001 Apr; 19(23-24):3301-10. PubMed ID: 11312029 [TBL] [Abstract][Full Text] [Related]
19. A comparison of the immune responses induced by antigens in three different archaeosome-based vaccine formulations. Jia Y; Akache B; Deschatelets L; Qian H; Dudani R; Harrison BA; Stark FC; Chandan V; Jamshidi MP; Krishnan L; McCluskie MJ Int J Pharm; 2019 Apr; 561():187-196. PubMed ID: 30836154 [TBL] [Abstract][Full Text] [Related]
20. Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators. Tandrup Schmidt S; Foged C; Korsholm KS; Rades T; Christensen D Pharmaceutics; 2016 Mar; 8(1):. PubMed ID: 26978390 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]